Showing 6701-6710 of 8785 results for "".
- ASDS Hosts New 'Expertise Summit'https://practicaldermatology.com/news/asds-hosts-new-expertise-summit/2468191/More than 50 dermatologic surgeons and dermatology residents gathered in Chicago, Illinois, on September 7-8 for a new course from the American Society for Dermatologic Surgery (ASDS), titled “ASDS Expertise Summit: Surgery. Injectables.” Practical Dermatology Editorial Board member Dr. As
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked
- Age-related Fibroblast Changes Drive Melanoma in Males, Study Sayshttps://practicaldermatology.com/news/age-related-fibroblast-changes-drive-melanoma-males-study-says/2468115/Age-related changes in fibroblasts contribute to development of aggressive, treatment-resistant melanoma in males, according to a Johns Hopkins Kimmel Cancer Center study published in Cell. The authors of the study, Dr. Ashani Weeraratna and colleagues, had previously shown in studies that
- Study: Melanoma Declining Among Ages 30-59 in Swedenhttps://practicaldermatology.com/news/study-melanoma-declining-among-ages-30-59-sweden/2468114/Melanoma incidence and mortality rates have declined in recent years among 30- to 59-year-olds in Sweden, according to a recent study published in JAMA Dermatology. A cohort study involving Sweden’s entire population found a continuous rise in primary invasive cutaneous melanoma incidence
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t
- Analysis Shows High Incidence of Skin Eruptions with Tebentafusp in Uveal Melanomahttps://practicaldermatology.com/news/high-incidence-skin-eruptions-tebentafusp-uveal-melanoma/2468062/Tebentafusp-associated skin toxicity was prevalent in patients treated for metastatic uveal melanoma, a recent study reported. Study researchers looked at a cohort study of 33 patients treated with tebentafusp and identified skin symptoms in 26 patients (median follow-up of 21.5 months for
- Analysis: COX1 Genotype Determines Fish Oil’s Efficacy Against ADhttps://practicaldermatology.com/news/analysis-cox1-genotype-determines-fish-oils-efficacy-against-ad/2467997/A secondary analysis of a randomized clinical trial indicated prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation may reduce the risk of childhood atopic dermatitis (AD) in a genotype-specific manner. Researchers for the analysis reported that mothers carrying t
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f